Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 471 for “"CML"”.
-
Identifying regulators of chronic myeloid leukaemic (CML) stem cell quiescence and discovering effective novel therapies for CML relapse
<p>Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm characterised by the presence of Philadelphia (Ph) chromosome. The standard treatment is tyrosine kinase inhibitors (TKI), while they achieve remission in many patients, the majority will relapse on cessation of therapy. This …
-
FROM CML TO CMYLIFE: A lifelong journey
Contains fulltext : 239943.pdf (Publisher’s version ) (Open Access)
-
A Mechanized Theory of Communication Analysis in CML
For this master's thesis, I have developed a formal semantics of a language with concurrent processes (or threads), an initial formal analysis, along with related theorems and formal proofs. The language under analysis is a very simplified version of Concurrent ML. The formal analysis recasts an …
-
Investigating the role of hypoxia in CML metabolism
Chronic myeloid leukaemia (CML) is a blood cancer arising from a haematopoietic stem cell (HSC) carrying the aberrant chromosomal translocation t (9;22) (q34; q11). The resulting “Philadelphia Chromosome” hosts the fusion oncogene BCR::ABL1, which encodes for a constitutive active non-receptor …
-
In vitro cytogenic studies in chronic myeloid leukemia (CML)
In chronic myeloid leukemia (CML), neoplastic transformation occurs in a single pluripotent hemopoietic stem cell. The differentiated progeny of this clone predominate in vivo so that in most patients all the proliferating bone marrow cells bear the unique chromosomal marker of the transformed …
-
TKI resistance in CML cell lines : investigating resistance pathways.
Chronic myeloid leukaemia (CML) is characterised by the presence of the Philadelphia chromosome which harbours the Bcr-Abl oncogene. BCR-ABL is a constitutively active tyrosine kinase that can be inhibited by rationally designed tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib and …
-
Characterization of hemopoietic stem cells in chronic myeloid leukemia (CML)
… transformation In chronic myeloid leukemia (CML) is a pluripotent hemopoietic stem cell, from which differentiated blood cells of the myeloid and lymphoid lineages Eire normally derived throughout adult life. CML is one of the best defined hematologic malignancies, being characterized by a …
-
LASP1 – ein neuer, phosphorylierungs-abhängiger Bindungspartner von CrkL in CML
… mit einer chronischen myeloischen Leukämie (CML) zulassen sollen. Zudem konnte, wie bereits bei zahlreichen anderen, soliden Tumorerkrankungen, eine signifikante Überexpression des lasp1-Gens in CML-Zellen nachgewiesen werden.Basierend auf diesen neuen Erkenntnissen beschäftigte ich mich im …
-
Expression and function of drug transporters in primitive CML cells
Chronic myeloid leukaemia (CML) is a stem cell (SC) disorder initiated by the reciprocal translocation between chromosome 9 and 22, giving rise to the Philadelphia (Ph) chromosome and the resulting expression of the oncogenic fusion protein BCR-ABL. The current first line of treatment is imatinib …
-
The Role of Dysregulated Transcription Factors in Drug Resistant CML
… is central to chronic myeloid leukaemia (CML) pathology. Clinical treatment of CML with the kinase inhibitor Imatinib Mesylate (IM) is a fundamental success. However, 15-20% of CML patients develop drug resistance. For the majority of patients, the challenge is to understand how leukaemic …
-
Anwendung mathematischer Modelle zur Vorhersage des Therapieverlaufs von CML-Patienten
Hintergrund Die chronische myeloische Leukämie (CML) ist eine myeloproliferative Er- krankung, die aufgrund ihres Modellcharakters unter der Behandlung mit Tyrosin-Kinase- Inhibitoren (TKI) gut für eine Beschreibung mittels computerbasierter Modelle geeignet ist. Grundlage für die Entstehung einer …
-
Isolation and characterisation of CML and normal quiescent haemopoietic stem cells
… of quiescent stem cells from both normal and CML samples and characterisation of the properties of these rare populations. To isolate these specific cell populations, enrichment of the stem cell fraction was achieved by selection methods based on the stem cell marker CD34. Positive or negative …
-
Phosphorylation of Beclin 1 by BCR-ABL suppresses autophagy in CML
… and maintenance of chronic myelogenous leukemia (CML). Imatinib and second-generation BCR-ABL tyrosine kinase inhibitors (TKIs) serve now as standard therapies for Ph+ patients. However, disease persistence occurs frequently and one of the major reasons was considered to be insensitivity of CML …
-
Identifizierung und funktionelle Charakterisierung von microRNAs bei Imatinib-Therapieresistenz der CML
Obwohl die Therapie der CML in der Klinik durch Implementierung von Tyrosinkinase-Inhibitoren (TKI) maßgeblich verbessert wurde, sprachen aufgrund von Resistenzen 30 % der Patient*innen nicht auf Imatinib an. Ursächlich für diese ist unter anderem die Resistenzbildung durch kleine nichtkodierende …
-
Defining CP-CML patient subsets associated with poor imatinib uptake and response.
… of chronic phase chronic myeloid leukaemia (CP-CML) patients. Although most patients will achieve excellent clinical (haematological, cytogenetic and molecular) responses on imatinib, it is clear that a subset of patients will respond poorly, or fail imatinib therapy. Currently, up to 35% of …
-
RAD52 DNA Binding Activity Can Be Targeted to Eliminate CML Stem Cells
… (ROS), which induce oxidative DNA damage. CML cells accumulate excessive amounts of ROS-induced DNA damage which can be converted to potentially lethal DNA double strand breaks (DSBs). BCR-ABL1 stimulates enhanced Rad51-mediated DSB repair by the homologous recombination repair (HRR) …
-
GM-CSF protection of CML CD34+ cells from the inhibitory effect of imatinib.
… to imatinib. In addition it was aimed to examine CML cell production of GM-CSF. Findings suggest that non-CD34+ cells may be a source of GM-CSF.
Page 1 of 24